Akatinol Memantine, 10 mg 30 pcs

Akatinol Memantine is a myorelaxant of central action.

Being a non-competitive antagonist of N-methyl-D-aspartate (NMDA)-receptors it has modulating effect on glutamatergic system.

It regulates ion transport, blocks calcium channels, normalizes membrane potential, improves nerve impulse transmission, improves cognitive processes, memory and learning ability, and increases daily activity.

Indications

Active ingredient

Composition

Active substance:

Memantine hydrochloride 10 mg;

Ancillary substances:

Lactose;

MCC;

Colloidal silicon dioxide;

talc;

magnesium stearate:

methacrylic acid copolymer;

sodium lauryl sulfate;

polysorbate 80;

triacetin;

simethicone emulsion;

talt.

How to take, the dosage

Akatinol Memantine is taken orally,with meals. Dosing regimen is set individually. It is recommended to start treatment with prescribing the least effective doses.

In adults with dementia during the 1st week of therapy – in a dose of 5 mg/day, the 2nd week – in a dose of 10 mg/day, the 3rd week – in a dose of 15-20 mg/day. If necessary, further weekly dose increase by 10 mg to reach a daily dose of 30 mg.

The optimal dose is reached gradually, increasing the dose each week.

Interaction

Concomitant use with L-dopa drugs, dopamine agonists, anticholinergic agents may increase their effect.

Concomitant use with barbiturates, neuroleptics may decrease the effect of the latter. Co-administration may change (increase or decrease) the effect of dantrolene or baclofen; therefore the doses of the drugs should be selected individually. Concomitant administration with amantadine, ketamine and dexamethorphan should be avoided.

Possible increase in plasma levels of cimetidine, procainamide, quinidine, quinine and nicotine when concomitantly administered with memantine. There may be a decrease in levels of hydrochlorothiazide when concomitantly taken with memantine.

Special Instructions

Patients with moderate to severe dementia with Alzheimer’s disease usually have impaired ability to drive vehicles and operate complex machinery.

In addition, memantine may cause changes in reaction speed, so patients treated as outpatients should use extra caution when driving or operating machinery.

Contraindications

Side effects

Adverse reactions are classified according to clinical manifestations (according to the involvement of certain organ systems) and by frequency of occurrence: Very common – ≥1/10; common – ≥1/100-

In the body as a whole – general adverse reactions Frequent Headache

Rarely Fatigue Infections

Rarely Fungal infections

Mental disorders Frequently Sleepiness

/p>

Rarely Confusion

Rarely Hallucinations

Frequency not determined

Psychotic reactions

Cardiovascular disorders

Rarely Hypertension

/p>

Rarely Venous Thrombosis/Thromboembolism

Gastrointestinal Disorders

Often Constipation

Rarely Nausea, Vomiting

Frequency not determined Pancreatitis

Disorders of the central and peripheral nervous systembr>

Often Dizziness

Rarely Gait disturbance

Very rarely Seizures

/p>

Hallucinations have been observed mainly in patients with Alzheimer’s disease at the stage of severe dementia.

There have been anecdotal reports of these adverse reactions when the drug is used in clinical practice (data obtained after the drug was commercially available).

Overdose

Symptoms: increased severity of side effects.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Pregnancy use

It is contraindicated in pregnancy. Breastfeeding should be stopped during treatment.

Similarities